Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 0.81 |
| ▸ | PDE4B | Q07343 | 20/20 | 0.81 |
| ▸ | PDE4C | Q08493 | 20/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 20/20 | 0.81 |
| ▸ | CHRM3 | P20309 | 19/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430133 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4419067 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4431257 | 0.75 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4423256 | 0.75 | PDE10A (0.61) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4418653 | 0.75 | PDE10A (0.61) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4431348 | 0.74 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4431395 | 0.74 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL460823 | 0.74 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4422424 | 0.73 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4426333 | 0.73 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544675-B2 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2009-06-09 | — | — | US | disclosed |
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2006-04-06 | — | — | US | disclosed |
| EP-1499598-A1 | CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | UCB, S.A. (BE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003087064-A1 | CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | UCB, S.A. (BE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | PDE7A, CHRM3, PDE4B | PDE4A 5/4885PDE4B 3/4885PDE4C 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.